US medical device Dexcom shares fall 40% - full year sales forecast revised downward

2024/7/26 13:01 JST (some excerpts)
It temporarily fell 41% due to overtime trading, then moved around 36% lower
Sales forecasts for blood sugar monitoring devices for type 1 diabetics were lowered
US medical device manufacturer Dexcom plummeted due to US stock market overtime trading on the 25th. It was viewed as evidence that the company revised downward the 2024 full-year sales forecast for continuous blood sugar monitoring devices particularly needed by type 1 diabetics.
　　Dexcom revealed in the presentation materials on this day that the full-year sales forecast was lowered from 4 billion to 4 billion 50 million dollars (about 615 billion to 623 billion yen) and the conventional 4.2 billion to 4.3 billion 50 million dollars.